What 3D-Matrix Medical Inc. does

3D-Matrix Medical Inc. (株式会社スリー・ディー・マトリックス / 3-D Matrix, Ltd.) is a Japanese medical technology company incorporated in Tokyo on May 19, 2004, and listed on the Tokyo Stock Exchange Growth Market under securities code 7777 since October 24, 2011. The company is built on a self-assembling peptide technology platform (RADA16) discovered by Dr. Shuguang Zhang at MIT in 1992, which it licenses globally from MIT. The platform spans three business domains: surgical treatment (hemostatic materials), tissue regeneration (wound healing, anti-adhesion, cosmetic surgery, bone and cardiac muscle regeneration), and drug delivery systems (DDS) for nucleic-acid therapeutics in oncology and malignant pleural mesothelioma.

The company's commercial portfolio centers on two flagship products. PuraStat® is an absorbable local hemostatic medical device composed of three amino acids (arginine, alanine, aspartic acid) that self-assembles into a transparent gel upon contact with blood or body fluids, approved in Japan (Class IV medical device, Approval No. 30200BZX00236000), CE marking countries, and the United States, and sold directly to hospitals via field sales representatives engaging KOLs in gastroenterology endoscopy. PuraMatrix™ is a first-generation self-assembling peptide hydrogel research reagent available in standard, high-concentration, GMP-grade, and functionalized (PRG, SDP, PFS) variants for 3D cell culture, tissue engineering, and regenerative-medicine research, distributed globally under exclusive agreements with BD Biosciences and Corning Japan's Life Sciences Division. A six-program development pipeline (PuraBond, PuraGel, PuraDerm, Puraiift, TDM-812, MIRX002) extends the platform into anti-adhesion, wound healing, mucosal lifting, and nucleic-acid DDS indications.

3D-Matrix generates revenue primarily through direct medical-device sales (PuraStat) to Japanese university, national, and core hospitals, complemented by research-reagent sales (PuraMatrix) through channel partners, freemium distribution to academic institutions under MTA agreements, and inbound/outbound licensing related to the underlying MIT technology. The company maintains wholly-owned operating subsidiaries in the United States, France, the United Kingdom, the Netherlands, Singapore, and Australia, supporting global commercialization and local regulatory compliance. As of April 30, 2023, the company reported ¥2,314 million in sales revenue and 108 employees (group basis); it is led by President and Representative Director Toshi Amanuma (appointed April 2026) and Chairman Keiji Nagano, with Robert S. Langer (MIT) serving as Medical, Science and Technology Advisor.

Name

3D-Matrix Medical Inc.

Legal name

株式会社スリー・ディー・マトリックス (3-D Matrix, Ltd.)

Website

https://3d-matrix.co.jp

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

3D-Matrix Medical Inc. is a Tokyo-based medical technology company that develops self-assembling peptide biomaterials (PuraStat hemostat, PuraMatrix research reagent) for endoscopic surgery, tissue regeneration, and nucleic-acid drug delivery, selling to hospitals worldwide and to academic researchers via BD Biosciences and Corning Japan.

Ownership category

akta.pro rank

Product category

Medical Biomaterials (Hemostatic Devices)

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Self-assembling peptides
• Hemostatic materials
• Medical biomaterials
• Tissue regeneration
• Drug delivery systems

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Device Sales: Sales of approved medical devices including PuraStat® hemostatic material. Approved in Japan (医疗器械承認番号：30200BZX00236000), CE marking countries, and US markets.
2. Research Reagent Sales: PuraMatrix™ research reagent products sold through sales partner Corning Japan. Also provided free to academic institutions through MTA agreements.
3. Licensing Royalties: Technology licensed from MIT for self-assembling peptide platform. Pipeline products under development in partnership.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

3D-Matrix Medical Inc. manufactures and sells PuraStat®, an absorbable local hemostatic medical device based on self-assembling peptide technology, approved in Japan, CE-marking countries, and the US for endoscopic and surgical procedures. The company also sells PuraMatrix™, a self-assembling peptide research reagent (with standard, high-concentration, GMP, and modified variants) for 3D cell culture, tissue engineering, and regenerative medicine research. The underlying MIT-licensed self-assembling peptide platform is also being extended into drug delivery systems (DDS) for nucleic acid medicines.

Product overview

3D-Matrix Medical Inc. is a MIT-licensed medical technology company developing products based on self-assembling peptide technology discovered at MIT in 1992. The product portfolio centers on two main offerings: (1) PuraStat® - an absorbable local hemostatic medical device for endoscopic procedures, approved in Japan, CE marking countries, and the US; and (2) PuraMatrix™ - a first-generation self-assembling peptide hydrogel research reagent available in standard, high-concentration, and modified variants (PRG, SDP, PFS) for 3D cell culture, tissue engineering, and regenerative medicine research. The company also offers GMP-grade PuraMatrix™ for clinical applications. The technology platform spans three medical domains: surgical treatment (hemostatic materials), tissue regeneration (wound healing, anti-adhesion), and drug delivery systems (DDS) for nucleic acid medicines. Pipeline products include PuraBond, Puraiift, PuraGel, PuraDerm, TDM-812, and MIRX002 in various stages of development.

Differentiator

Problem solved

Functional benefit

Brands

• PuraStat: Absorbable local hemostatic material (PuraStat in English markets, ピュアスタット in Japan) — a transparent peptide-based hemostatic gel for endoscopic and surgical use. Medical device approval number: 30200BZX00236000. Cleared as a Class IV managed medical device.
• PuraMatrix
• PuraBond
• PuraGel
• PuraDerm
• ピュアリフト
• PuraMatrix

Products and services

• PuraStat® (ピュアスタット®) Absorbable local hemostatic material for endoscopic use. A transparent, fully synthetic peptide solution (composed of arginine, alanine, and aspartic acid) that self-assembles (gels) upon contact with blood or body fluids, physically covering bleeding sites. Available in sterile pre-filled syringes ready-to-use. Approved in Japan (高度管理医疗器械), CE marking countries, and the United States.
• PuraMatrix™ First-generation self-assembling peptide hydrogel research reagent. A 1% peptide solution available in 1mL or 5mL vials. Forms nanofibers similar to natural extracellular matrix (ECM) under physiological conditions. Used for 3D cell culture, tissue engineering, and regenerative medicine research.
• High Concentration PuraMatrix™ High concentration hydrogel version of PuraMatrix™. Provided as 1mL vials with concentration adjustment up to 3% depending on application requirements. Used for research applications requiring higher gel strength.
• Modified Peptides (PRG, SDP, PFS) Functional modified peptides with added motifs: PRG (RGDS adhesion motif from fibronectin), SDP (YIGSR adhesion motif from laminin), PFS (bone marrow homing factor sequence). Used for specific research applications requiring enhanced cell adhesion or targeting.
• PuraMatrix™ GMP Grade Good Manufacturing Practice (GMP) grade PuraMatrix™ manufactured for clinical applications. Available for researchers interested in clinical implementation of the self-assembling peptide platform.

Quantifiable outcome

• Rat pharmacokinetics: 75.6% disappearance 14 days after intraperitoneal administration
• +1 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core, major and minor.

• MIT (Massachusetts Institute of Technology)coreStrategic or Co-development Partner · 1 January 1992Licensed self-assembling peptide technology from MIT, discovered by Dr. Shuguang Zhang. Foundation of entire company technology platform.
• Kyoto University (京都大学)coreStrategic or Co-development PartnerAcademic partnership for self-assembling peptide research. Multiple departments including Faculty of Medicine, Institute for Frontier Medical Sciences, and Translational Research Center.
• University of Tokyo / Tokyo University (東京大学)coreStrategic or Co-development PartnerAcademic research partnership through Faculty of Medicine and Institute of Medical Science for peptide applications.
• Osaka University (大阪大学)coreStrategic or Co-development PartnerAcademic partnership with Faculty of Medicine for regenerative medicine and DDS research.
• Keio University (慶応大学)coreStrategic or Co-development PartnerAcademic research partnership for medical applications of self-assembling peptide technology.
• BD BiosciencesmajorChannel Partner/ Reseller/ DistributorExclusive distribution agreement for PuraMatrix research reagent products.
• Corning Japan Life Sciences Division (コーニングジャパン株式会社 ライフサイエンス部門)majorChannel Partner/ Reseller/ DistributorSales partner for research reagent products including PuraMatrix, high concentration PuraMatrix, and modified peptides.
• MIRX002 License PartnerminorStrategic or Co-development PartnerLicensing arrangement for MIRX002 (malignant pleural mesothelioma treatment) development, under development by licensee.
• Robert S. Langer (MIT Professor)coreStrategic or Co-development PartnerMedical, Science and Technology Advisor. Professor of Chemical Engineering at MIT.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Smith & Nephew: Smith & Nephew operates a global advanced wound management and surgical device portfolio. Its regenerative medicine and wound healing products (e.g., PICO, OASIS) overlap with 3D-Matrix's PuraDerm wound healing pipeline and PuraStat surgical applications.
• Baxter International: Baxter is a global medical products company with established hemostatic agents (Floseal, Tisseel) used in surgical procedures. It competes directly with PuraStat in endoscopic and surgical hemostasis markets, offering a broader portfolio but with broader resources and sales reach.
• Becton Dickinson (BD): BD is both a partner (distributes PuraMatrix research reagent) and a comparable company through its biosciences division that sells life science research tools. As a large medtech incumbent with global commercialization capabilities, it represents both partnership and competitive overlap.
• Takeda Pharmaceutical: Takeda is a major Japanese biopharmaceutical company with biologic therapeutic capabilities. As a Japanese incumbent with global reach, it represents both a domestic competitor and a potential partner/acquirer for 3D-Matrix's therapeutic peptide pipeline.
• Johnson & Johnson (Ethicon): Ethicon, a J&J subsidiary, markets Surgicel and Evicel hemostatic products widely used in surgery. As the dominant incumbent in surgical hemostasis, it competes with PuraStat across endoscopic and open surgical procedures globally.

Emerging players

• Galderma: Galderma operates in dermatology and aesthetic/cosmetic medicine, where 3D-Matrix's PuraDerm wound healing pipeline targets cosmetic surgery applications. While not a direct competitor today, it represents a relevant partner and comparable in 3D-Matrix's planned cosmetic surgery market expansion.

Direct peers

• CryoLife: CryoLife specializes in surgical adhesives, sealants, and hemostatic agents used in cardiac and vascular surgery (BioGlue, CryoPatch). Its biomaterial-focused portfolio directly competes with 3D-Matrix's surgical hemostasis product line.
• Cohera Medical: Cohera developed TissuGlu and other synthetic surgical adhesives and anti-adhesion products. Its focus on synthetic, biocompatible surgical adhesives directly parallels 3D-Matrix's PuraGel anti-adhesion pipeline and PuraStat surgical approach.
• Integra LifeSciences: Integra develops DuraSeal and other surgical sealants/hemostats focused on neurosurgical and reconstructive applications. Its specialty surgical device focus and pipeline of biomaterial products make it a direct comparable in surgical hemostasis and tissue repair.

Others

• Corning Life Sciences: Corning Japan Life Sciences is a sales partner for PuraMatrix research reagents, but Corning's broader life sciences portfolio (cell culture, 3D culture systems) competes with and complements 3D-Matrix's research reagent offerings in tissue engineering and 3D cell culture.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3D-Matrix Medical Inc.